Roche Announces Interim Results for Phase III SKYSCRAPER-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

TOKYO, May 11, 2022 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Roche issued a press release regarding interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer of the investigational anti-TIGIT immunotherapy tiragolumab. Please refer to the link below for details of the press release: Roche reports interim results for phase III SKYSCRAPER-01 study in PD-L1-high metastatic non-small cell lung cancer https://www.roche.com/media/releases/med-cor-2022-05-11

The release as fetched from its publisher. chugai-pharm.co.jp ↗